These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32450321)

  • 1. A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.
    Liu W; Jiang X; Zu Y; Yang Y; Liu Y; Sun X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2020 Aug; 200():112447. PubMed ID: 32450321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines.
    Benner A; Bonifazi A; Shirataki C; Temme L; Schepmann D; Quaglia W; Shoji O; Watanabe Y; Daniliuc C; Wünsch B
    ChemMedChem; 2014 Apr; 9(4):741-51. PubMed ID: 24677663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
    Dey S; Schepmann D; Wünsch B
    Bioorg Med Chem; 2018 Jan; 26(2):501-508. PubMed ID: 29254894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enantiomerically Pure 2-Methyltetrahydro-3-benzazepin-1-ols Selectively Blocking GluN2B Subunit Containing N-Methyl-D-aspartate Receptors.
    Tewes B; Frehland B; Schepmann D; Robaa D; Uengwetwanit T; Gaube F; Winckler T; Sippl W; Wünsch B
    J Med Chem; 2015 Aug; 58(15):6293-305. PubMed ID: 26186074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
    Lütnant I; Schepmann D; Wünsch B
    Eur J Med Chem; 2016 Jun; 116():136-146. PubMed ID: 27061977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
    Fernandes A; Wojcik T; Baireddy P; Pieschl R; Newton A; Tian Y; Hong Y; Bristow L; Li YW
    Eur J Pharmacol; 2015 Nov; 766():1-8. PubMed ID: 26325093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
    Dey S; Temme L; Schreiber JA; Schepmann D; Frehland B; Lehmkuhl K; Strutz-Seebohm N; Seebohm G; Wünsch B
    Eur J Med Chem; 2017 Sep; 138():552-564. PubMed ID: 28704758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ
    Thum S; Schepmann D; Ayet E; Pujol M; Nieto FR; Ametamey SM; Wünsch B
    Eur J Med Chem; 2019 Sep; 177():47-62. PubMed ID: 31129453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands.
    Thum S; Schepmann D; Kalinin DV; Ametamey SM; Wünsch B
    ChemMedChem; 2018 Dec; 13(23):2522-2529. PubMed ID: 30312542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies.
    Szermerski M; Börgel F; Schepmann D; Haider A; Betzel T; Ametamey SM; Wünsch B
    ChemMedChem; 2018 May; 13(10):1058-1068. PubMed ID: 29522653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.
    Pinard E; Alanine A; Bourson A; Büttelmann B; Heitz M; Mutela Ramanjit Gill V; Trube G; Wyler R
    Bioorg Med Chem Lett; 2002 Sep; 12(18):2615-9. PubMed ID: 12182873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.
    Dey S; Schepmann D; Wünsch B
    Bioorg Med Chem Lett; 2016 Feb; 26(3):889-893. PubMed ID: 26750254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenol-Benzoxazolone bioisosteres: Synthesis and biological evaluation of tricyclic GluN2B-selective N-methyl- d-aspartate receptor antagonists.
    Markus A; Schreiber JA; Goerges G; Frehland B; Seebohm G; Schepmann D; Wünsch B
    Arch Pharm (Weinheim); 2022 Sep; 355(9):e2200147. PubMed ID: 35606894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride).
    Sun L; Chiu D; Kowal D; Simon R; Smeyne M; Zukin RS; Olney J; Baudy R; Lin S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):563-70. PubMed ID: 15075380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands.
    Gitto R; De Luca L; Ferro S; Scala A; Ronsisvalle S; Parenti C; Prezzavento O; Buemi MR; Chimirri A
    Bioorg Med Chem; 2014 Jan; 22(1):393-7. PubMed ID: 24290063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.
    Wagner M; Schepmann D; Ametamey SM; Wünsch B
    Bioorg Med Chem; 2019 Aug; 27(16):3559-3567. PubMed ID: 31255496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists.
    Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J
    Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
    Rath S; Schepmann D; Wünsch B
    Bioorg Med Chem; 2017 Oct; 25(20):5365-5372. PubMed ID: 28797770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and preliminary evaluation of novel
    Sun JY; Kumata K; Chen Z; Zhang YD; Chen JH; Hatori A; Fu HL; Rong J; Deng XY; Yamasaki T; Xie L; Hu K; Fujinaga M; Yu QZ; Shao T; Collier TL; Josephson L; Shao YH; Du YF; Wang L; Xu H; Zhang MR; Liang SH
    Acta Pharmacol Sin; 2021 Mar; 42(3):491-498. PubMed ID: 32661351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling of a phenyl-amidine class of NMDA receptor antagonists and the rational design of new triazolyl-amidine derivatives.
    Abreu PA; Castro HC; Paes-de-Carvalho R; Rodrigues CR; Giongo V; Paixão IC; Santana MV; Ferreira JM; Caversan OM; Leão RA; Marins LM; Henriques AM; Farias FM; Albuquerque MG; Pinheiro S
    Chem Biol Drug Des; 2013 Feb; 81(2):185-97. PubMed ID: 22985449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.